Published by Bianca Boorer on 11th January 2017
(ShareCast News) - Evgen Pharma, a clinical stage drug development company focused on the treatment of cancer and neurological conditions, has received a positive interim safety review from the independent Data Safety Monitoring Board (DSMB) for its Phase II double-blind placebo-controlled SAS trial of SFX-01 in subarachnoid haemorrhage (SAH).